Compare BMI & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMI | GPCR |
|---|---|---|
| Founded | 1905 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.9B |
| IPO Year | 1994 | 2023 |
| Metric | BMI | GPCR |
|---|---|---|
| Price | $160.54 | $54.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $188.57 | $103.36 |
| AVG Volume (30 Days) | 286.3K | ★ 1.1M |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 13.24 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.50 | N/A |
| Revenue Next Year | $6.74 | N/A |
| P/E Ratio | $33.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $139.14 | $15.80 |
| 52 Week High | $256.08 | $94.90 |
| Indicator | BMI | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.40 | 49.04 |
| Support Level | $142.68 | $17.89 |
| Resistance Level | $163.16 | $61.20 |
| Average True Range (ATR) | 5.03 | 3.45 |
| MACD | 1.07 | 1.45 |
| Stochastic Oscillator | 97.13 | 78.11 |
Badger Meter is a provider of water management solutions. The company's solutions encompass measurement and control hardware, connectivity and communication, data visualization and software. Badger Meter has globalised operations, with the vast majority of revenue derived from the USA. The company is an innovator in flow measurement, water quality and control products, serving water utilities, municipalities and commercial and industrial customers world-wide.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.